Related Experiment Videos
A unique mucin immunoenhancing peptide with antitumor properties
Lynn M Herbert1, Joseph F Grosso, Mantley Dorsey
1Department of Microbiology & Immunology, University of Miami School of Medicine, Miami, Florida 33101, USA.
Cancer Research
|November 3, 2004
Summary
A unique peptide from secreted human mucin 1 (MUC1) enhances the immune response, offering protection against mammary tumors and other cancers. This peptide shows potential as an immunotherapy agent.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Mammary tumor cells (DA-3) implanted in BALB/c mice cause tumor growth, metastasis, and death.
- Transfection of DA-3 cells with transmembrane (DA-3/TM) or secreted (DA-3/sec) human mucin 1 (MUC1) isoforms alters tumor behavior.
Purpose of the Study:
- To investigate the in vivo behavior of MUC1 isoforms in mammary tumor cells.
- To determine if the secreted MUC1 isoform or its unique peptide can elicit an anti-tumor immune response.
Main Methods:
- Implantation of transfected DA-3 cells (DA-3/TM, DA-3/sec, DA-3/neo) into immunocompetent BALB/c and nude mice.
- Pre-exposure of mice to DA-3/sec cells or the 11 amino acid peptide derived from secreted MUC1.
- Challenge with various tumor types (DA-3/TM, DA-3/neo, K7, RENCA, Lewis lung carcinoma) to assess protection.
Main Results:
- DA-3/sec cells failed to grow in immunocompetent mice but formed tumors in nude mice.
- Pre-exposure to DA-3/sec cells protected BALB/c mice against subsequent challenges with DA-3/TM, DA-3/neo, K7, and RENCA tumors.
- The 11 amino acid peptide from secreted MUC1 partially protected against tumor challenges in a strain-independent manner.
Conclusions:
- A unique peptide within the secreted MUC1 isoform possesses immunoenhancing properties.
- This MUC1-derived peptide demonstrates potential as a novel agent for cancer immunotherapy.